- Round ID
- FR-00453
- Stage
- Series B
- Round name
- Series B
- Amount
- £75.5M (extended with further £10M from British Patient Capital, 2023)
Dated funding evidence
OMass Therapeutics
Series B · £75.5M (extended with further £10M from British Patient Capital, 2023) · 2023-05-01
Reported round£75.5M (extended with further £10M from British Patient Capital, 2023)Series B
- Disclosure date
- 2023-05-01
- Reported currency
- GBP
- Companies House
- 10028228
- Evidence sources
- 2
2023-05-01Series B£75.5M (extended with further £10M from British Patient Capital, 2023)
Resolved investor records
GVLead investorNorthpond VenturesLead investorSanofi VenturesLead investorSynconaInvestorOxford Science EnterprisesInvestorOxford UniversityInvestorBritish Patient CapitalInvestor
Investor links inherit this round’s named source and date. Resolved links use an exact canonical investor name; unresolved names remain unlinked.
Record fields
What the source states
Amounts, currency, stage and investor names are preserved as reported. No FX conversion, valuation inference or current-holding claim is added.
- Lead investors
- GV, Northpond Ventures, Sanofi Ventures
- Other investors
- Syncona, Oxford Science Enterprises, Oxford University, British Patient Capital
- Source layers
- VC research snapshot, Live Chris T D1
- Snapshot
- 2026-08-15
Named evidence
Source trail
This page is published only when the record has a resolved company, disclosure date, round stage and at least one retained source URL.